دورية أكاديمية
Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia:final results of a prospective multicenter phase 2 HOVON study
| العنوان: | Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia:final results of a prospective multicenter phase 2 HOVON study |
|---|---|
| المؤلفون: | van Gelder, M., van Oers, M. H., Alemayehu, W. G., Abrahamse-Testroote, M. C. J., Cornelissen, J. J., Chamuleau, M. E., Zachee, P., Hoogendoorn, M., Nijland, M., Petersen, E. J., Beeker, A., Timmers, G-J, Verdonck, L., Westerman, M., de Weerdt, O., Kater, A. P. |
| المصدر: | van Gelder , M , van Oers , M H , Alemayehu , W G , Abrahamse-Testroote , M C J , Cornelissen , J J , Chamuleau , M E , Zachee , P , Hoogendoorn , M , Nijland , M , Petersen , E J , Beeker , A , Timmers , G-J , Verdonck , L , Westerman , M , de Weerdt , O & Kater , A P 2016 , ' Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia : final results of a prospective multicenter phase 2 HOVON study .... |
| سنة النشر: | 2016 |
| المجموعة: | University of Groningen research database |
| مصطلحات موضوعية: | Cisplatin/administration & dosage, Disease-Free Survival, Hematopoietic Stem Cell Transplantation/methods, Humans, Leukemia, Lymphocytic, Chronic, B-Cell/mortality, Middle Aged, Neoplasm, Residual, Risk, Survival Rate, Transplantation Conditioning/methods, Treatment Outcome |
| الوصف: | Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) <1 year after fludarabine or <2 years after fludarabine-based immunochemotherapy or R/R with del(17p). Twenty-nine patients received ⩾3 cycles of R-DHAP and sixteen <3 cycles (4 because of disease progression, 8 for toxicity and 4 toxic deaths). Overall rate of response to R-DHAP was 58%, 31 (67%) proceeded to alloSCT after conditioning with fludarabine and 2 Gy TBI. Twenty (65%) remained free from progression at 2 years after alloSCT, including 17 without minimal residual disease. Intention-to-treat 2-year PFS and overall survival of the 46 patients were 42 and 51% (35.5 months median follow-up); del(17p) or fludarabine refractoriness had no impact. R-DHAP followed by alloSCT is a reasonable treatment to be considered for high-risk CLL patients without access or resistance to targeted therapies. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://research.rug.nl/en/publications/85d0bf27-7708-4117-86d3-7c1dbd63e264Test |
| DOI: | 10.1038/bmt.2016.9 |
| الإتاحة: | https://doi.org/10.1038/bmt.2016.9Test https://hdl.handle.net/11370/85d0bf27-7708-4117-86d3-7c1dbd63e264Test https://research.rug.nl/en/publications/85d0bf27-7708-4117-86d3-7c1dbd63e264Test |
| حقوق: | info:eu-repo/semantics/closedAccess |
| رقم الانضمام: | edsbas.7EA73D4B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/bmt.2016.9 |
|---|